Katrina Erny-Albrecht

Statistics

Publications

Citations

433

H-Index

Active since

1996

Affiliations

Novo Nordisk (United States)(Current)

Health Economics and Outcomes Research (United Kingdom)

University of California, San Francisco

University of Cologne

Katrina Erny-Albrecht is an author at Novo Nordisk (United States) specializing in diabetes mellitus, pharmacoeconomics, and cost-effectiveness analysis.

ORCID

Publications per year

1996–2009

Publications

ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis

Chuan-Hsiung Chang, Gary K. Scott, Wen-Lin Kuo et al. · Oncogene · 1997 · 182 citations

Medicine, Molecular Biology, Molecular Genetics +11

Ets regulation of the erbB2 promoter

Gary K. Scott, Chuan-H Chang, Katrina Erny-Albrecht et al. · Oncogene · 2000 · 77 citations

Life Sciences, Genetics, Molecular Biology +12

Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH

William J. Valentine, Andrew Palmer, Katrina Erny-Albrecht et al. · Advances in Therapy · 2006 · 44 citations · Full text

Pharmacy, Endocrinology, Pharmacoeconomics +13

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland

Michael Brändle, Katrina Erny-Albrecht, G Goodall et al. · International Journal of Clinical Pharmacology and Therapeutics · 2009 · 29 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes

William J. Valentine, G Goodall, Mark Aagren et al. · Advances in Therapy · 2008 · 24 citations · Full text

Pharmacy, Endocrinology, Pharmacoeconomics +14

1–5 of 9